Create Free Account

By creating account you will get access to hot stocks & personalised emails

Immutep Ltd

Healthcare AU IMM

0.42AUD
-0.01(2.33%)

Last update at 2024-05-02T06:10:00Z

Day Range

0.410.43
LowHigh

52 Week Range

0.220.46
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -39.89635M -32.21079M -29.90259M -13.46819M -18.34398M
Minority interest - - - - -
Net income -39.89635M -32.21083M -29.90262M -13.46823M -16.27064M
Selling general administrative 8.68M 7.21M 6.28M 6.34M 6.13M
Selling and marketing expenses - - - - -
Gross profit - 0.17M - 7.49M 0.14M
Reconciled depreciation - 3.00M - 2.08M 1.88M
Ebit -41.43131M -33.93755M -19.56058M -16.01888M -20.41733M
Ebitda - -31.87409M -20.72271M -13.93924M -18.53818M
Depreciation and amortization - 2.06M -1.16213M 2.08M 1.88M
Non operating income net other - - - - -
Operating income -40.63135M -33.93755M -19.56058M -16.01888M -20.41733M
Other operating expenses - 34.01M 19.66M 22.56M 19.10M
Interest expense 0.02M 0.09M 0.00983M 0.01M 0.00000M
Tax provision 0.00000M 0.00005M 0.00003M 0.00004M 0.00000M
Interest income 0.74M 0.33M 0.11M 1.40M 0.46M
Net interest income 0.92M 0.19M 0.10M 0.19M 0.40M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.00003M 0.00003M 0.00004M -2.07334M
Total revenue 1.13M 0.17M 0.42M 7.49M 0.14M
Total operating expenses 41.43M 34.01M 19.66M 22.56M 19.10M
Cost of revenue - - - - 16.59M
Total other income expense net 0.62M 1.73M -10.34201M 2.55M 2.07M
Discontinued operations - - - - -
Net income from continuing ops -39.89635M -46.82423M -29.90262M -13.46823M -18.34398M
Net income applicable to common shares -39.89635M -32.21083M -29.90262M -13.46823M -18.34398M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 147.45M 102.17M 82.03M 46.60M 40.54M
Intangible assets 9.38M 10.44M 12.74M 15.08M 16.84M
Earning assets - - - - -
Other current assets 0.05M 3.55M 2.17M 1.44M 1.74M
Total liab 10.98M 8.09M 8.76M 13.30M 16.15M
Total stockholder equity 136.47M 94.08M 73.27M 33.30M 24.39M
Deferred long term liab - - - - -
Other current liab 4.14M 3.37M 3.31M 1.60M 2.74M
Common stock 446.27M 367.41M 313.42M 242.99M 221.09M
Capital stock 446.27M 534.09M 313.42M 242.99M 221.09M
Retained earnings -339.93053M -302.33521M -274.64222M -275.70606M -262.23783M
Other liab 0.16M 0.12M 0.81M 1.01M 3.21M
Good will 0.11M 0.11M 0.11M 0.11M 0.11M
Other assets 2.52M 0.50M 0.45M - -
Cash 123.42M 80.00M 60.13M 26.32M 16.57M
Cash and equivalents 3.59M 0.30M 8.28M 13.53M -
Total current liabilities 9.77M 6.41M 5.34M 3.36M 5.30M
Current deferred revenue - - - - -
Net debt -122.18945M -78.26131M -57.31301M -17.27055M -8.92527M
Short term debt 0.19M 0.17M 0.21M 0.13M 0.00000M
Short long term debt - - - - -
Short long term debt total 1.23M 1.73M 2.82M 9.05M 7.64M
Other stockholder equity 6.43M 5.43M 44.15M 75.68M 75.20M
Property plant equipment 0.47M 0.31M 0.31M 0.25M 0.05M
Total current assets 134.97M 90.81M 68.42M 31.15M 23.54M
Long term investments - - - - -
Net tangible assets 126.98M 83.52M 60.42M 18.10M 7.44M
Short term investments - - - - -
Net receivables 7.97M 8.37M 6.12M 3.39M 5.23M
Long term debt 0.84M 2.11M 2.53M 8.79M 7.64M
Inventory - -1.10832M - - -
Accounts payable 5.45M 2.87M 1.82M 1.64M 2.56M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 30.13M 29.00M 34.49M 66.01M 65.53M
Additional paid in capital - - - - -
Common stock total equity - - - 242.99M 221.09M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.52M 0.50M 0.45M - 17.00M
Deferred long term asset charges - - - - -
Non current assets total 12.48M 11.36M 13.61M 15.45M 17.00M
Capital lease obligations 0.39M 0.41M 0.29M 0.26M -
Long term debt total 1.04M 1.56M 2.61M 8.92M 7.64M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.03100M -0.04500M -0.02400M -0.01900M -0.04143M
Change to liabilities 3.27M 1.44M 1.38M -2.12600M 1.40M
Total cashflows from investing activities -0.08274M -0.02291M -0.01560M -0.01935M -0.04143M
Net borrowings -0.21197M -0.22254M -0.21438M -0.07754M -0.07754M
Total cash from financing activities 76.04M 50.33M 52.68M 20.48M 8.01M
Change to operating activities -0.90011M -0.74727M -0.54342M 0.32M 0.02M
Net income -39.89635M -32.21083M -29.90262M -13.46823M -18.34398M
Change in cash 43.42M 19.40M 34.27M 9.75M -6.90754M
Begin period cash flow 80.00M 60.59M 26.32M 16.57M 23.48M
End period cash flow 123.42M 80.00M 60.59M 26.32M 16.57M
Total cash from operating activities -35.88300M -30.22975M -17.64034M -10.83934M -15.28640M
Issuance of capital stock 80.08M 52.98M 43.31M 22.03M 4.87M
Depreciation 2.06M 2.06M 2.07M 2.08M 1.88M
Other cashflows from investing activities - - - - -
Dividends paid 0.00000M 0.00000M - 0.00000M -
Change to inventory - - - - -
Change to account receivables -1.60770M -2.24938M -2.83054M 1.90M -1.76213M
Sale purchase of stock 80.08M 52.98M 54.57M 22.03M 8.79M
Other cashflows from financing activities -3.85600M -2.42715M 9.59M -1.47493M 3.14M
Change to netincome 1.71M 1.48M 12.18M 0.46M 1.29M
Capital expenditures 0.05M 0.02M 0.02M 0.02M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.66M -1.56119M 1.75M 8.26M 4.27M
Stock based compensation - 1.49M - - -
Other non cash items - -0.00804M 29.90M 11.39M 16.46M
Free cash flow -35.93000M -30.25267M -17.65594M -10.85869M -15.32783M

Fundamentals

  • Previous Close 0.43
  • Market Cap499.31M
  • Volume2648672
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-41.26886M
  • Revenue TTM3.93M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM -32.75147M
  • Diluted EPS TTM-0.04

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMM
Immutep Ltd		 -0.01 2.33% 0.42 - 7.50 113.41 3.85 994.70 -8.4894
CSL
CSL Ltd		 0.90 0.33% 275.39 35.44 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.13 0.89% 14.80 748.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 0.12 0.63% 19.18 15.98 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 -0.03 2.73% 1.07 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Immutep Ltd

Australia Square, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Marc Voigt CEO, MD, CFO, Chief Bus. Officer & Exec. Director 1973
Ms. Deanne Miller LLB COO, Gen. Counsel & Joint Company Sec. 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer, Chief Medical Officer & Exec. Director 1955
Ms. Indira Naidu Joint Company Sec. NA
Mr. Christian Mueller Director of Clinical Devel. & Regulatory Affairs NA
Mr. Shengfei Fang Fin. Director & Assistant Company Sec. NA
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973
Ms. Deanne Miller LLB COO, General Counsel & Joint Company Secretary 1977
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer & Executive Director 1955
Mr. Marc Voigt CEO, MD, CFO, Chief Business Officer & Executive Director 1973

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.